




Supplementary material Figure S1. Agarose gel electrophoresis of PCR amplification of *icaA* (188 bp) and *icaD* (198 bp) locus. Lane 1: 100 pb DNA molecular size marker; Lanes 3-5: PCR amplification of *icaA*; Lanes 6-8: PCR amplification of *icaD*. Lane 2: Negative control; Lanes 3 to 8: PCR amplicons obtained with DNA of *S. aureus*. Lane 3: *S. aureus* ATCC 43300, Lane 4: S1; Lane 5: S3; Lane 6: S4; Lane 7: S8; Lane 8: S10.



Supplementary material Figure S2. Agarose gel electrophoresis of PCR amplification of *fnbA* gene (191 bp) and *fnbB* gene (201 bp). Lane 1: 100 bp DNA molecular size marker; Lane 2: negative control; Lanes 3-5: PCR amplification of *fnbA* gene; Lanes 6-7: PCR amplification of *fnbB* gene; Lane 3 to 7: PCR amplicons obtained with DNA amplification of *S. aureus*; Lane 3: *S. aureus* ATCC 43300; Lane 4: S8; Lane 5: S13; Lane 6: *S. aureus* ATCC 43300; Lane 7: S20.



Supplementary material Figure S3. Agarose gel electrophoresis of polymerase chain reaction (PCR) amplification *cna* gene (192 bp) and *clfA* gene (1kb). Lane 1, 100 bp DNA molecular size marker. Lane 2 negative control; Lanes 3-6 PCR amplification of *cna* gene, lanes 7-8 PCR amplification of *clfA* gene. Lane 3 to 8 PCR amplicons obtained with DNA amplification of *S. aureus*. Lane 3, *S. aureus* ATCC 43300; Lane 4, S1; Lane 5, S6; Lane 6, S15; Lane 7, *S. aureus* ATCC 43300; Lane 8, S9.



Supplementary material Figure S4. Agarose gel electrophoresis of polymerase chain reaction (PCR) amplification of *mecA* (140 pb), *norA* (620 bp), *NorB* (213 bp) and *blaZ* (172 bp) genes. Lane 1: 100 bp DNA molecular size marker; Lanes 2-3 PCR amplification of *mecA* gene. Lanes 4-5 PCR amplification of *norA* gene. Lanes 6-7 PCR amplification of *norB* gene and lane 8 PCR amplification of *blaZ* gene. Lanes 2: *S. aureus* ATCC 43300; Lanes 3 to 8 PCR amplicons obtained with DNA amplification of *S. aureus*. Lane 2: S1; Lane 3: S3; Lane 4: S8; Lane 5: S9; Lane 6: S6; Lane 7: S11; Lane 8: S23.

Supplementary material Table S1. Study of antimicrobial susceptibility profile of clinical *S. aureus* strains

Antibiotics	<i>Staphylococcus aureus</i> strains																							
	S1		S2		S3		S4		S5		S6		S7		S8		S9		S10		S11		S12	
	MIC	I	MIC	I	MIC	I	MIC	I	MIC	I	MIC	I	MIC	I	MIC	I	MIC	I	MIC	I	MIC	I	MIC	I
Gentamicin	<2	S	>8	R	<2	S	2	S	2	S	2	S	2	S	>8	R	2	R	2	S	>0.5	R	2	S
Cefoxitin	<2	R	>8	R	>8	R	>8	R	>8	R	>8	R	>8	R	8	R	8	R	2	S	>8	R	>8	R
Cefotaxime	<8	R	8	R	8	R	>32	R	>32	R	>32	R	8	R	8	R	8	R	2	S	8	R	>32	R
Ceftaroline	<0.25	S	0.5	S	0.5	S	1	S	1	S	1	S	0.5	S	0.5	S	0.5	S	8	S	8	S	>2	R
Ampicillin	1	R	>1	R	1	R	>1	R	>1	R	>1	R	1	R	1	R	1	R	1	R	1	R	1	R
Penicillin G	1	R	>1	R	0.5	R	>1	R	>1	R	>1	R	>1	R	0.5	R	1	R	0.25	S	0.25	S	>1	R
Oxacillin	>2	R	>2	R	>2	R	>2	R	>2	R	>2	R	>2	R	2	S	2	R	0.25	S	0.5	R	>2	R
Daptomycin	1	S	1	S	1	S	1	S	1	S	1	S	1	S	1	S	1	S	1	S	1	S	1	S
Trimethoprim	>4	R	1	S	1	S	1	S	1	S	1	S	1	S	1	S	1	S	1	S	<10	S	1	S
Teicoplanin	8	S	>16	R	1	S	1	S	1	S	1	S	1	S	1	S	1	S	1	S	<0.25	S	2	S
Vancomycin	<1	S	1	S	1	S	1	S	1	S	1	S	1	S	1	S	1	S	1	S	1	S	1	S
Clindamycin	<0.5	S	>2	R	0.5	S	0.5	S	0.5	S	0.5	S	0.5	S	0.5	S	0.5	S	0.5	S	<0.25	S	>2	R
Erythromycin	>4	R	>4	R	0.25	S	>4	R	>4	R	0.25	S	>4	R	0.25	S	0.25	S	>4	R	>8	R	>4	R
Linezolid	4	S	1	S	1	S	1	S	1	S	1	S	1	S	1	S	1	S	1	S	2	S	1	S
Mupirocin High level	<256	S	256	S	256	S	256	S	256	S	256	S	256	S	256	S	256	S	<256	S	<256	S	256	S
Nitrofurantoin	<16	S	16	S	16	S	16	S	16	S	16	S	16	S	16	S	16	S	16	S	<16	S	32	S
Ciprofloxacin	2	R	0.5	S	0.5	S	0.5	S	0.5	S	0.5	S	0.5	S	0.5	S	0.5	S	0.5	S	0.5	S	>2	R
Levofloxacin	<1	S	1	S	1	S	1	S	1	S	1	S	1	S	1	S	1	S	0.5	S	0.25	S	>4	R
Moxifloxacin	<0.5	S	0.5	S	0.5	S	0.5	S	0.5	S	0.5	S	0.5	S	0.5	S	0.5	S	0.5	S	<0.25	S	>2	R
Rifampin	<0.5	S	0.5	S	0.5	S	0.5	S	0.5	S	0.5	S	0.5	S	0.5	S	0.5	S	0.5	S	<0.5	S	>2	R
Tetracycline	>8	R	>8	R	0.5	S	0.5	S	0.5	S	0.5	S	>8	R	0.5	S	0.5	S	0.5	S	<1	S	8	R
Tigecycline	<0.25	S	0.25	S	0.25	S	0.25	S	0.25	S	0.5	S	0.25	S	0.5	S	0.25	S	0.5	S	<0.12	S	0.25	R
% of Resistance		40.9		45.4		22.7		27.2		27.2		22.7		31.8		22.7		27.2		0.9		27.2		63.6
Antibiotics	S13		S14		S15		S16		S17		S18		S19		S20		S21		S22		S23		S24	
	MIC	I	MIC	I	MIC	I	MIC	I	MIC	I	MIC	I	MIC	I	MIC	I	MIC	I	MIC	I	MIC	I	MIC	I
Gentamicin	>0.5	R	<2	S	<2	S	<2	S	<2	S	>16	R	<0.5	S	<2	S	<2	S	<2	S	<2	S	>8	R
Cefoxitin	>8	R	<4	S	<2	S	<2	R	<2	S	<2	S	<2	S	>8	R	<2	R	>8	R	>8	R	8	R
Cefotaxime	8	R	8	R	<2	S	8	R	<2	S	8	R	8	R	<8	R	>8	R	<8	R	32	R	<8	R
Ceftaroline	<8	R	<8	R	16	R	<8	R	<8	R	<8	R	<8	R	>2	R	>32	R	2	I	1	S	>2	R
Ampicillin	>16	R	>16	R	>16	R	>16	R	>16	R	>16	R	>16	R	>1	R	>1	R	>1	R	>1	R	>1	R
Penicillin G	>25	R	<1	S	>25	R	>25	R	0.13	S	>25	R	>25	R	>1	R	>0.25	R	>1	R	1	R	>1	R

Oxacillin	0.5	R	<1	S	0.5	S	>2	R	<0.25	S	>4	R	>4	R	0.5	S	>2	R	0.5	S	>2	R	>2	R
Daptomycin	1	S	<1	S	1	S	2	R	<1	S	<1	S	<1	S	<1	S	>4	R	<1	S	<1	S	1	S
Trimethoprim	<10	S	<1	S	1	S	<1	S	<1	S	40	R	<10	S	<1	S	<1	R	<1	S	<1	S	1	S
Teicoplanin	<0.25	S	<1	S	>4	R	>4	R	<1	S	8	R	>32	R	>16	R	1	S	>16	R	<1	S	1	S
Vancomycin	<0.25	S	<1	S	<1	S	<1	S	1	S	1	S	>32	R	>16	R	<0.5	R	>16	R	<1	S	0.5	S
Clindamycin	<0.25	S	<0.25	S	1	S	1	S	<0.5	S	>8	R	>8	R	>2	R	<0.25	S	>2	R	<0.5	R	0.25	S
Erythromycin	>8	R	>8	R	<0.5	S	<0.5	S	<0.25	S	>8	R	>8	R	>4	R	<1	S	>4	R	>4	R	1	S
Linezolid	2	S	2	S	0.5	S	0.5	S	<1	S	1	S	1	S	>4	R	2	S	2	S	<1	S	2	S
Mupirocin High level	<1	S	<1	S	<1	S	8	R	2	S	<1	S	<1	S	<256	S	<256	S	<256	S	<256	S	256	S
Nitrofurantoin	<16	S	<16	S	2	S	2	S	2	S	<16	S	<16	S	<16	S	<16	S	<16	S	<16	S	16	S
Ciprofloxacin	<0.5	S	<0.5	S	256	S	256	S	256	S	<0.5	S	<0.5	S	<0.5	S	<0.5	S	>2	R	<0.5	S	0.5	S
Levofloxacin	0.25	S	<1	S	16	S	16	S	16	S	>8	R	<0.12	S	<1	S	<1	S	>4	R	<1	S	1	S
Moxifloxacin	<0.25	S	<0.25	S	0.5	S	>2	R	0.5	S	2	R	<0.25	S	<0.5	S	<0.5	S	2	R	<0.5	S	0.5	S
Rifampin	<0.5	S	<0.5	S	0.5	S	2	S	0.5	S	<0.5	S	>32	R	<0.5	S	<0.5	S	1	S	<0.5	S	0.5	S
Tetracycline	<1	S	<1	S	0.5	S	0.5	S	0.5	S	<1	S	<1	S	0.5	R	<0.5	S	>8	R	<0.5	S	>8	R
Tigecycline	<0.12	S	<1	S	0.5	S	0.5	S	0.5	S	<0.12	S	<0.12	S	0.5	S	<0.5	S	<0.25	S	<0.25	S	<0.25	S
% of Resistance		36.3		18.1		18.1		45.4		9.1		54.5		45.4		50		40.9		54.5		31.8		36.3